<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01482819</url>
  </required_header>
  <id_info>
    <org_study_id>CR-005031</org_study_id>
    <nct_id>NCT01482819</nct_id>
  </id_info>
  <brief_title>Evaluation of Daytime Corneal Swelling During Wear of Galyfilcon A Lenses</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate corneal swelling, limbal redness, and endothelial
      bleb response to wearing galyfilcon A lenses in asian eyes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2011</start_date>
  <completion_date type="Actual">December 1, 2011</completion_date>
  <primary_completion_date type="Actual">December 1, 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal Swelling</measure>
    <time_frame>after 8 hours of lens wear</time_frame>
    <description>measured in microns using the Optical Low Coherence Reflectometry (OLCR) Pachymeter. This pachymeter gives corneal thickness measurements to the accuracy of 1 micron (Âµm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Limbal Redness</measure>
    <time_frame>after 8 hours of lens wear</time_frame>
    <description>grade scale of 0 to 4, where 0=None, 1=Trace, 2=Mild, 3=Moderate, 4=Severe; reported as an average grade.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelia Blebs</measure>
    <time_frame>after 20 minutes of lens wear</time_frame>
    <description>0 to 100% of area; measured as a percentage of corneal area with blebs.</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
Lotrafilcon A
Spectacles
Galyfilcon A Plus
Polymacon
Galyfilcon A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
Galyfilcon A Plus
Galyfilcon A
Lotrafilcon A
Polymacon
Spectacles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
Galyfilcon A
Polymacon
Galyfilcon A Plus
Spectacles
Lotrafilcon A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
Spectacles
Lotrafilcon A
Polymacon
Galyfilcon A Plus
Galyfilcon A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
Polymacon
Galyfilcon A
Spectacles
Galyfilcon A Plus
Lotrafilcon A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
Galyfilcon A
Galyfilcon A Plus
Polymacon
Lotrafilcon A
Spectacles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 7</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
Polymacon
Spectacles
Galyfilcon A
Lotrafilcon A
Galyfilcon A Plus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 8</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
Galyfilcon A Plus
Lotrafilcon A
Galyfilcon A
Spectacles
Polymacon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 9</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
Lotrafilcon A
Galyfilcon A Plus
Spectacles
Galyfilcon A
Polymacon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 10</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
Spectacles
Polymacon
Lotrafilcon A
Galyfilcon A
Galyfilcon A Plus</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>galyfilcon A</intervention_name>
    <description>contact lenses worn bilaterally for 8-12 hours</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_label>Sequence 7</arm_group_label>
    <arm_group_label>Sequence 8</arm_group_label>
    <arm_group_label>Sequence 9</arm_group_label>
    <arm_group_label>Sequence 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>galyfilcon A plus</intervention_name>
    <description>contact lenses worn bilaterally for 8-12 hours</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_label>Sequence 7</arm_group_label>
    <arm_group_label>Sequence 8</arm_group_label>
    <arm_group_label>Sequence 9</arm_group_label>
    <arm_group_label>Sequence 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>lotrafilcon A</intervention_name>
    <description>contact lenses worn bilaterally for 8-12 hours</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_label>Sequence 7</arm_group_label>
    <arm_group_label>Sequence 8</arm_group_label>
    <arm_group_label>Sequence 9</arm_group_label>
    <arm_group_label>Sequence 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>polymacon</intervention_name>
    <description>contact lenses worn bilaterally for 8-12 hours</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_label>Sequence 7</arm_group_label>
    <arm_group_label>Sequence 8</arm_group_label>
    <arm_group_label>Sequence 9</arm_group_label>
    <arm_group_label>Sequence 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>spectacles</intervention_name>
    <description>habitual spectacles owned by subject, non-specific manufacturer</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_label>Sequence 7</arm_group_label>
    <arm_group_label>Sequence 8</arm_group_label>
    <arm_group_label>Sequence 9</arm_group_label>
    <arm_group_label>Sequence 10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be of legal age (i.e. 18 years)

          -  Be of Asian descent and have âAsian eyeâ identifying features (see Appendix A)

          -  Be mentally competent, willing and able to sign a written informed consent form.

          -  Have contact lens distance sphere requirement in the range 1.00D to 6.00D.

          -  Have spectacle astigmatism &lt;1.25D in each eye

          -  Currently wear soft contact lenses (for at least 3 months prior to the trial ) without
             experiencing difficulties or contact lens related complications

          -  Have had an oculo-visual examination within the previous 12 months.

          -  Have normal eyes with no evidence of abnormality or disease. For the purposes of this
             study a normal eye is defined as one having:

               -  No evidence of lid abnormality or infection

               -  No conjunctival abnormality or infection

               -  No clinically significant slit lamp findings (i.e. edema, staining, scarring,
                  vascularization, infiltrates or abnormal opacities)

               -  No other active ocular disease

        Exclusion Criteria:

          -  Requires concurrent ocular medication.

          -  Clinically significant (Grade 3 or 4) corneal staining (FDA scale), corneal stromal
             haze, corneal vascularization, tarsal abnormalities, bulbar hyperemia, limbal
             hyperemia, or any other abnormality of the cornea that would contraindicate contact
             lens wear.

          -  Has had refractive surgery.

          -  Has had any anterior ocular surgery. Has had any other ocular surgery or injury within
             8 weeks immediately prior to enrolment for this study.

          -  History of abnormal lachrymal secretions.

          -  Pre-existing ocular irritation that would preclude contact lens fitting.

          -  Keratoconus or other corneal irregularity.

          -  Extended lens wear in last 3 months.

          -  PMMA, hybrid or RGP lens wear in the previous 8 weeks

          -  Any systemic illness which would contraindicate lens wear or the medical treatment of
             which would affect vision or successful lens wear.

          -  Has diabetes

          -  Known/reported infectious disease (e.g., hepatitis, tuberculosis) or an
             immunosuppressive disease (e.g., HIV).

          -  History of chronic eye disease (e.g. glaucoma or ARMD).

          -  Pregnancy, lactating, or planning a pregnancy at the time of enrolment.

          -  Participation in any concurrent clinical trial or in last 30 days.

          -  Family member or employee of the clinical site, investigator or other study staff.

          -  Currently wears habitual contact lenses on an EW basis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Hawthorn</city>
        <state>Victoria</state>
        <zip>3122</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2011</study_first_submitted>
  <study_first_submitted_qc>November 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2011</study_first_posted>
  <results_first_submitted>January 8, 2015</results_first_submitted>
  <results_first_submitted_qc>April 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 30, 2015</results_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>Twenty-one subjects were enrolled, and 19 subjects completed the study per protocol. Two subjects were discontinued. There were no ineligible subjects.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who were screened, gave consent, enrolled, and were randomized in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>Twenty-one subjects were enrolled, and 19 subjects completed the study per protocol. Two subjects were discontinued. There were no ineligible subjects.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.7" spread="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Corneal Swelling</title>
        <description>measured in microns using the Optical Low Coherence Reflectometry (OLCR) Pachymeter. This pachymeter gives corneal thickness measurements to the accuracy of 1 micron (Âµm)</description>
        <time_frame>after 8 hours of lens wear</time_frame>
        <population>Subjects who were enrolled, randomized, and completed the study. One eye from each subject was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Spectacles</title>
            <description>No lenses, glasses wear only, testing is done on open eye once glasses are removed. Acted as a negative control.</description>
          </group>
          <group group_id="O2">
            <title>Galyfilcon A Plus</title>
            <description>Test article</description>
          </group>
          <group group_id="O3">
            <title>Galyfilcon A</title>
            <description>test article</description>
          </group>
          <group group_id="O4">
            <title>Lotrafilcon A</title>
            <description>test article</description>
          </group>
          <group group_id="O5">
            <title>Polymacon</title>
            <description>test article</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Swelling</title>
          <description>measured in microns using the Optical Low Coherence Reflectometry (OLCR) Pachymeter. This pachymeter gives corneal thickness measurements to the accuracy of 1 micron (Âµm)</description>
          <population>Subjects who were enrolled, randomized, and completed the study. One eye from each subject was measured.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="569.42" spread="36.0709"/>
                    <measurement group_id="O2" value="574.64" spread="39.7804"/>
                    <measurement group_id="O3" value="575.57" spread="37.6229"/>
                    <measurement group_id="O4" value="578.99" spread="41.4960"/>
                    <measurement group_id="O5" value="573.79" spread="36.1644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Limbal Redness</title>
        <description>grade scale of 0 to 4, where 0=None, 1=Trace, 2=Mild, 3=Moderate, 4=Severe; reported as an average grade.</description>
        <time_frame>after 8 hours of lens wear</time_frame>
        <population>Subjects who were enrolled, randomized, and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Spectacles</title>
            <description>No lenses, glasses wear only, testing is done on open eye once glasses are removed. Acted as a negative control.</description>
          </group>
          <group group_id="O2">
            <title>Galyfilcon A Plus</title>
            <description>Test article</description>
          </group>
          <group group_id="O3">
            <title>Galyfilcon A</title>
            <description>test article</description>
          </group>
          <group group_id="O4">
            <title>Lotrafilcon A</title>
            <description>test article</description>
          </group>
          <group group_id="O5">
            <title>Polymacon</title>
            <description>test article</description>
          </group>
        </group_list>
        <measure>
          <title>Limbal Redness</title>
          <description>grade scale of 0 to 4, where 0=None, 1=Trace, 2=Mild, 3=Moderate, 4=Severe; reported as an average grade.</description>
          <population>Subjects who were enrolled, randomized, and completed the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.2479"/>
                    <measurement group_id="O2" value="0.83" spread="0.3023"/>
                    <measurement group_id="O3" value="0.77" spread="0.3085"/>
                    <measurement group_id="O4" value="0.91" spread="0.3087"/>
                    <measurement group_id="O5" value="1.14" spread="0.3363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endothelia Blebs</title>
        <description>0 to 100% of area; measured as a percentage of corneal area with blebs.</description>
        <time_frame>after 20 minutes of lens wear</time_frame>
        <population>Subjects who were enrolled, randomized and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Spectacles</title>
            <description>No lenses, glasses wear only, testing is done on open eye once glasses are removed. Acted as a negative control.</description>
          </group>
          <group group_id="O2">
            <title>Galyfilcon A Plus</title>
            <description>Test article</description>
          </group>
          <group group_id="O3">
            <title>Galyfilcon A</title>
            <description>test article</description>
          </group>
          <group group_id="O4">
            <title>Lotrafilcon A</title>
            <description>test article</description>
          </group>
          <group group_id="O5">
            <title>Polymacon</title>
            <description>test article</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelia Blebs</title>
          <description>0 to 100% of area; measured as a percentage of corneal area with blebs.</description>
          <population>Subjects who were enrolled, randomized and completed the study.</population>
          <units>percentage of area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.97" spread="3.3703"/>
                    <measurement group_id="O2" value="8.86" spread="3.9396"/>
                    <measurement group_id="O3" value="10.93" spread="6.6020"/>
                    <measurement group_id="O4" value="10.31" spread="6.6747"/>
                    <measurement group_id="O5" value="8.50" spread="3.6000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>Twenty-one subjects were enrolled, and 19 subjects completed the study per protocol. Two subjects were discontinued. There were no ineligible subjects.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daria Wicks, Senior Clinical Research Manager</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care</organization>
      <phone>904-443-1391</phone>
      <email>RA-ClnclStds@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

